Table 1 Patient characteristics before and after cladribine treatment
From: Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis
WHO functional class | 6-MWD (m) | FVC (l) | ΔFVC (ml) | FEV1 (l) | ΔFEV1 (ml) | FEV1/FVC (%) | DLco (%) | PaO2 (mmHg) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cladribine | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | ||
Patient 1 M, 45 y | IV | III | 60 | 220 | 2.67 (56%) | 2.93 (62%) | +260 | 1.00 (28%) | 1.15 (32%) | +150 | 38 | 37 | 15 | 16 | 60 (3 l) | 65 (2 l) |
Patient 2 F, 37 y | II | 0 | NA | NA | 2.54 (66%) | 3.54 (95%) | +1,000 | 1.98 (61%) | 2.90 (90%) | +920 | 95 | 82 | 58 | NA | NA | NA |
Patient 2 F, 37 y relapse | II | 0 | NA | NA | 3.33 (87%) | 4.0 (110%) | +670 | 2.43 (75%) | 3.10 (95%) | +670 | 72 | 79 | 52 | 70 | NA | NA |
Patient 3 F, 55 y | II-III | I | NA | NA | 2.88 (112%) | 3.30 (126%) | +420 | 1.96 (89%) | 2.30 (104%) | +340 | 69 | 71 | 67 | 62 | 82.5 | NA |
Patient 4 M, 50 y | II | II | 495 | NA | 4.30 (98%) | 4.43 (101%) | +130 | 1.40 (41%) | 1.61 (47%) | +210 | 32 | 36 | 66 | 68 | 79.5 | 91.5 |
Patient 5 F, 40 y | II-III | II-III | 267 | 282 | 2.6 (78%) | 2.6 (79%) | +0 | 0.8 (29%) | 0.9 (31%) | +100 | 29 | 18 | 30 | 28 | 82.5 | 84 |